Humacyte, Inc.

NASDAQ:HUMA

1.41 (USD) • At close May 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 7.22800010.7900000.0311.3010.2330.1770.2410.690.1550.1240.9140.1980.255
Cost of Revenue 3.61401.8231.7913.3781.3151.9952.0852.1252.04714.6522.0510.0490.0490.24415.13713.19914.69211.82314.364
Gross Profit 3.6140-1.823-1.7917.412-1.315-1.995-2.085-2.125-2.016-13.351-1.8180.1280.1920.446-14.982-13.075-13.778-11.625-14.109
Gross Profit Ratio 0.50000.6870000-65.032-10.262-7.8030.7230.7970.647-96.658-105.444-15.074-58.712-55.329
Reseach & Development Expenses 20.65622.92623.75321.26420.1818.55220.5417.27814.95717.33714.65216.31416.2515.38614.56815.13713.19914.69211.82314.364
General & Administrative Expenses 7.4327.3075.7465.3146.0026.073.0845.2345.8336.1885.185.6825.5545.3985.3914.7872.5973.4352.7243.257
Selling & Marketing Expenses 3.6140-1.823-1.791-3.378000000000000000
SG&A 11.0467.3073.9233.5232.6246.073.0845.2345.8336.1885.185.6825.5545.3985.3914.7872.5973.4352.7243.257
Other Expenses 00-0.72900.26600-0.266-0.048-0.0310-0.233-1.328-1.2520-0.1550000
Operating Expenses 31.70230.23327.67624.78722.80424.62223.62422.51220.7923.49418.53121.76321.62720.54319.26919.76915.67217.2132.7243.257
Operating Income -28.088-30.233-29.499-26.578-26.182-24.622-26.731-22.512-20.79-23.494-18.531-21.763-21.627-20.543-19.269-19.769-15.672-17.213-14.349-17.366
Operating Income Ratio -3.886000-2.4270000-757.871-14.244-93.403-122.186-85.241-27.926-127.542-126.387-18.833-72.47-68.102
Total Other Income Expenses Net 7.148-8.969-27.164-5.3181.076-1.3734.025-14.45717.07-1.78755.3991.93164.212-11.022.071-0.532-0.54-0.547-0.529-0.308
Income Before Tax -20.94-39.202-56.663-31.896-25.106-25.995-22.706-36.969-3.72-25.28136.868-19.83242.585-31.563-17.198-20.301-16.212-17.76-14.878-17.674
Income Before Tax Ratio -2.897000-2.3270000-815.51628.338-85.116240.593-130.967-24.925-130.974-130.742-19.431-75.141-69.31
Income Tax Expense -1.748001.748-28.0491.4631.7124.876-17.2950.1461.488-3.363-67.5867.7091.2150.00116.02117.71900
Net Income -20.94-39.202-56.663-31.896-25.106-25.995-22.706-61.84513.575-25.42736.868-16.46942.585-31.563-17.198-20.301-16.212-17.76-14.878-17.674
Net Income Ratio -2.897000-2.3270000-820.22628.338-70.682240.593-130.967-24.925-130.974-130.742-19.431-75.141-69.31
EPS 1.08-0.33-0.48-0.29-0.24-0.25-0.22-0.60.13-0.250.36-0.160.41-0.72-0.17-0.2-5.61-1.43-0.68-0.81
EPS Diluted 1.08-0.33-0.48-0.29-0.24-0.25-0.22-0.60.13-0.250.35-0.160.41-0.72-0.17-0.2-5.61-1.43-0.68-0.81
EBITDA -16.624-30.233-52.325-28.289-20.001-23.217-19.001-33.185-37.908-21.59340.388-16.34946.038-28.859-17.203-17.699-13.595-15.131-12.259-15.264
EBITDA Ratio -2.3000-1.8540000-696.54831.044-70.167260.102-119.747-24.932-114.187-109.637-16.555-61.914-59.859